Can Patients Stop Taking Blood Thinners After AF Ablation? The OCEAN Trial Sparks Debate.
The OCEAN trial reveals a potential paradigm shift in post-ablation care for atrial fibrillation (AF) patients. But is it safe to stop blood thinners for everyone?
In a groundbreaking study, the OCEAN trial has shown that patients with successful AF ablation may not need long-term blood thinners, but experts caution that this only applies to low-risk individuals.
New Orleans, LA—The OCEAN trial has revealed surprising results: patients treated with aspirin after successful AF ablation had similar stroke and adverse outcome risks compared to those on oral anticoagulation.
In the trial, investigators found that over 36 months, the rates of stroke, systemic embolism, and small cerebral infarctions detected by MRI were comparable between patients taking aspirin and those on the direct oral anticoagulant rivaroxaban.
Lead investigator Dr. Atul Verma believes these findings could change the game for some patients: "When considering the entire body of evidence, we see that certain patients can safely discontinue oral anticoagulation after successful ablation."
Dr. Verma suggests that patients with a CHA2DS2-VASc score of 1, 2, or even 3 might be candidates for stopping blood thinners. However, he emphasizes that the OCEAN trial had few recent stroke patients, so those with a recent stroke history may require a different approach.
This aligns with the ALONE-AF study, which also indicated that stopping oral anticoagulation post-ablation led to better clinical outcomes for low-risk patients.
But here's where it gets controversial: Current US and European guidelines advocate for long-term oral anticoagulation after AF ablation based on stroke risk calculations. The OCEAN trial challenges this approach, but experts warn that it's not a one-size-fits-all solution.
Dr. Verma highlights the motivation behind the trial: "Patients constantly ask if they can stop taking blood thinners, and we lacked the evidence to answer. The OCEAN trial was our attempt to provide clarity."
Dr. Oussama Wazni agrees that physicians often face the dilemma of whether to continue or discontinue blood thinners for AF ablation patients. He suggests that for low-risk patients in normal sinus rhythm, stopping the medication is a reasonable consideration.
However, real-world practice presents challenges. Dr. Wazni emphasizes the importance of patient conversations, as some low-risk patients may still experience strokes.
Dr. Christine Albert adds that silent AF and stroke risks are concerns post-ablation, as seen in older trials like AFFIRM. She believes the OCEAN trial offers valuable risk-benefit data to guide discussions with patients.
Trial Details:
The OCEAN trial, published in the New England Journal of Medicine, included 1,284 patients with successful AF ablation and a CHA2DS2-VASc score of 1 or more. Patients were randomized to aspirin or a modified dose of rivaroxaban.
Surprisingly, the trial was stopped early due to the high likelihood of similar outcomes in both groups. At 3 years, the primary composite outcome showed no significant difference between the rivaroxaban and aspirin groups.
Investigators were astonished by the low event rates in both arms. The annualized risks for the primary endpoint were significantly lower than expected.
Regarding safety, the rate of fatal or major bleeding was slightly higher in the rivaroxaban group, but overall, the trial suggests that low-risk patients may not need long-term blood thinners.
Expert Perspectives:
Dr. Michael Ghannam, an electrophysiologist, acknowledges the effectiveness of ablation in reducing AF burden and improving quality of life. However, he emphasizes that the impact on stroke risk is less clear.
While the OCEAN study provides valuable insights, Dr. Ghannam cautions against generalizing the findings to all patients. He suggests that low-risk patients with successful ablation can have more in-depth conversations about discontinuing blood thinners, especially those at high bleeding risk.
Dr. Wazni proposes that physicians hesitant to stop blood thinners could consider apixaban after ablation due to its lower bleeding risk. He highlights the reversibility of bleeding events compared to the potential devastation of a stroke.
The OPTION study, presented by Dr. Wazni, suggests that left atrial appendage occlusion (LAAO) might be a viable alternative, offering reduced bleeding risks and comparable outcomes to DOAC therapy.
